Investors interested in meeting the executive team and
hearing NeuroSense's strategy, updates, and upcoming catalysts are
invited to register for the webinar event.
CAMBRIDGE, Mass., Sept. 6,
2023 /PRNewswire/ -- NeuroSense Therapeutics
Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments
for severe neurodegenerative diseases, announced today it will host
an investor webinar conference on Tuesday,
September 12, 2023 from 8:30 AM to
9:15 AM Eastern Time.
NeuroSense's CEO, Alon Ben-Noon,
VP of R&D, Dr. Shiran Zimri, Chief Medical Officer, Dr.
Ferenc Tracik and VP of BD, Nedira
Salzman, will present to investors and analysts, followed by a
Q&A. The presentation will focus on NeuroSense's scientific
advances, its Phase 2b amyotrophic
lateral sclerosis (ALS) clinical trial design, endpoints, and
progress, Alzheimer Disease (AD) Phase 2 study design, endpoints,
and progress, as well as upcoming catalysts.
With the completion of a successful financing in June 2023, NeuroSense is in a strong financial
position with a capital runway beyond the expected readout of
topline data from the Phase 2b
PARADIGM trial in Q4 2023.
Investors interested in attending the event are invited to
register here or RSVP via email: Events@neurosense-tx.com.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the timing of top-line results of,
and the results of, the PARADIGM clinical trial, cash runway
estimate and the timing of patient enrollment in our Alzheimer's
Disease (AD) clinical trial. Further, forward-looking
statements are subject to a number of risks and uncertainties as a
result of which actual results could differ materially and
adversely from those anticipated or implied in the forward looking
statements. These risks include a delay in the reporting of
top-line results from PARADIGM clinical trial and a delay in
patient enrollment in our AD clinical trial; greater than
anticipated costs and expenses; the potential for PrimeC to safely
and effectively target ALS; preclinical and clinical data for
PrimeC; the timing of current and future clinical trials, timing
for reporting data; the nature, strategy and focus of the company
and further updates with respect thereto; the development and
commercial potential of any product candidates of the company; and
other risks and uncertainties set forth in NeuroSense's filings
with the Securities and Exchange Commission (SEC), including
NeuroSense's Annual Report on Form 20-F filed with the SEC on
March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date,
and NeuroSense Therapeutics Ltd. undertakes no duty to update such
information except as required under applicable law.
Logo -
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-to-host-investor-webinar-on-september-12-2023-301919182.html
SOURCE NeuroSense
